anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A therapeutic bacteriophage preparation in solid dry form is obtained by cultivating a strain of a pathogenic bacteria by submerged aerobic cultivation in an aqueous solution of a protein hydrolysate, effecting lysis of the bacteria by the corresponding bacteriophage, precipitating the bacteriophage from the lysate by means of an inorganic salt, e.g. ammonium sulphate, and drying the precipitate, preferably after admixture with 10% calcium gluconate.  The solid is then pressed into tablets or filled into capsules which are rendered enteric by coating with graphite or acetylphthalyl cellulose.  For parenteral use, the concentrate is desalted by dialysis.  The aqueous solution of protein hydrolipate may be an hydrolipate of beef, casein or soya bean containing 200 mg. per cent amine nitrogen.  In the example for the preparation of Dysenteric Phage Sonne, the aqueous medium contains beef hydrolipate (200 mg. per cent amine nitrogen), 0.5% sodium chloride and 0.1% sodium monohydrogen phosphate of pH 7.6.  After sterilization, it is inoculated with a suspension of Shigella sonnei and incubated 3 hours under submerged aerobic cultivation. It is then inoculated with Shigella sonnei phage and lipis allowed to continue until the culture clarifies and the total nitrogen in the medium is the same as at the beginning of the cultivation. The culture is heated to 56 DEG  C. to inactivate the bacteria but not the phage, filtered, cooled to 0 DEG C. and ammonium sulphate added to saturation.  10% calcium gluconate is added to the web precipitate and the mixture dried in vacuo.  Other therapeutic bacteriophages which may be made are those of typhus, paratyphus and other Salmonellas, Vibrio cholerae, E. coli, Staphylococcus and Proteus. They may be used for the treatment of man and animals.
BACKGROUND: Chronic diseases are associated with a high disease burden. Under- and overprovision of care as well as quality variation between health care providers persists, while current quality indicators rarely capture the patients' perspective. Capturing patient-reported outcome measures (PROMs) as well as patient-reported experience measures (PREMs) is becoming more and more important to identify gaps in care provision, prioritize services most valuable to patients, and aid patients' self-management.
OBJECTIVE: This study aims to measure the potential benefits and effectiveness of using electronic patient-reported outcome measures (ePROMs) and electronic patient-reported experience measures in a structured and population-based manner to enhance health care for chronic disease patients in Germany.
METHODS: This prospective cohort study aims to evaluate the potential benefits of PROM usage in patients with chronic diseases. We evaluate whether (1) digitally collected PROMs and PREMs can be used for health system performance assessment by generating a representative response of chronically diseased individuals with asthma, chronic obstructive pulmonary disease, diabetes, and coronary artery disease across Germany, and (2) based on the PROMs and PREMs, low-value care can be identified. As patient-reported outcomes (PROs) are rarely presented back to patients, (3) this study also examines patients' reactions to their PROM scores in the form of digital PRO feedback. For these purposes, randomly selected patients from a nationwide German insurer are digitally surveyed with generic and disease-specific PROMs and PREMs, as well as additional questions on their health-related behavior, 4 times over 1 year. Individual PRO feedback is presented back to patients longitudinally and compared to a peer group after each survey period. Patient-reported data is linked with health insurance data. Response rates, changes in health and experience outcomes over time, self-reported changes in health behavior, and health care system usage will be analyzed.
RESULTS: The PROMchronic study explores the usage of PROMs in patients with chronic diseases. Data collection began in October 2023, after the initial invitation letter. All the 200,000 potential patients have been invited to participate in the study. Data have not yet been analyzed. Publication of the interim results is planned for the autumn of 2024, and the results are planned to be published in 2025.
CONCLUSIONS: We aim to fill the research gap on the population-based usage of PROMs and PREMs in patients with chronic diseases and add to the current understanding of PROM data-sharing with patients. The study's results can thereby inform whether a health care system-wide approach to collecting PROMs and PREMs can be used to identify low-value care, assess quality variation within and across chronic conditions, and determine whether PRO feedback is helpful and associated with any changes in patients' health behaviors.
TRIAL REGISTRATION: German Clinical Trials Register DRKS00031656; https://drks.de/search/en/trial/DRKS00031656.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/56487.
The respective drugs to be used for incision-site infiltration were prepared by an independent study investigator in the two groups: Participates will receive peri-incisional scalp infiltration with 150 mg ropivacaine diluted to a total volume of 30 mL in 0.9% saline in the control group. The concentration of ropivacaine was 0.5% in both groups. The anesthesia protocol and monitoring were standardized for all patients. Monitoring, including blood pressure (BP), heart rate (HR), 5-lead electrocardiography (ECG), peripheral oxygen saturation (SpO2) and bispectral index (BIS) were continuously performed.
FIELD: medicine. SUBSTANCE: method involves administering 12.0 million MU of alpha interferon and 1.0 g of 5-fluorouracyl into the renal artery with concurrently embolizing it with Ivalon, hemostatic sponge and metal spirals. Immune therapy course is administered in postembolization period 2-3 days later using interleukin-2 once per two days alternating it with intramuscular injections of recombinant alpha interferon at a dose of 3.0 million MU/m 2 . Roncoleukin is advised to be intravenously drop-wise administered as interleukin-2 in 400 ml of physiological salt solution with 8.0 ml of 10% albumin added during 4 h. The patient is to be examination in future every 3 months. Signs being detected that the disease starts developing or the renal artery recanalization taking place, the treatment is repeated. Tumor node size being reduced or metastasis regress being observed, nephrectomy is to be advisable. EFFECT: enhanced effectiveness of treatment; prolonged remission period. 3 cl
PURPOSE:To improve attrition properties while keeping decaying properties, to decrease damage of a wet-processed tablet during processing and to make handling easy by filling a wet kneaded substance in a mold and molding it by compressing. CONSTITUTION:A wet kneaded substance is filled into a mold in the process A and the kneaded substance in the mold is coated with a powder in the process B and compression on the kneaded substance in the mold is performed in the process C and the kneaded substance is discharged in the process D. Here, an fat-soluble medicine and an excipient are mixed and the mixture is kneaded with an org. solvent or water as a wetting agent and a binder. In comparison with the case where a wet-processed tablet is prepared without compression, while decaying time is not changed and void vol. in the tablet is not decreased, attrition is remarkably improved, thereby. Therefore, damage of the wet- processed tablet is small during the process of packaging and handling is easy. In addition, as the wet-processed tablet contg. the fat-soluble medicine exhibits a short decaying time, it is possible for an aged person with decreased ability of swallowing to take it without water.
Esophagectomy is a complex and complication laden procedure. Despite centralization, variations in perioparative strategies reflect a paucity of evidence regarding optimal routines. The use of nasogastric (NG) tubes post esophagectomy is typically associated with significant discomfort for the patients. We hypothesize that immediate postoperative removal of the NG tube is non-inferior to current routines. All Nordic Upper Gastrointestinal Cancer centers were invited to participate in this open-label pragmatic randomized controlled trial (RCT). Inclusion criteria include resection for locally advanced esophageal cancer with gastric tube reconstruction. A pretrial survey was undertaken and was the foundation for a consensus process resulting in the Kinetic trial, an RCT allocating patients to either no use of a NG tube (intervention) or 5 days of postoperative NG tube use (control) with anastomotic leakage as primary endpoint. Secondary endpoints include pulmonary complications, overall complications, length of stay, health related quality of life. A sample size of 450 patients is planned (Kinetic trial: https://www.isrctn.com/ISRCTN39935085). Thirteen Nordic centers with a combined catchment area of 17 million inhabitants have entered the trial and ethical approval was granted in Sweden, Norway, Finland, and Denmark. All centers routinely use NG tube and all but one center use total or hybrid minimally invasive-surgical approach. Inclusion began in January 2022 and the first annual safety board assessment has deemed the trial safe and recommended continuation. We have launched the first adequately powered multi-center pragmatic controlled randomized clinical trial regarding NG tube use after esophagectomy with gastric conduit reconstruction.
BACKGROUND: Alpha1-antitrypsin (AAT) is a serine protease inhibitor that serves as a counterbalance to the activity of elastases, e.g., neutrophil elastase in lung tissue. AAT deficiency (AATD) is a rare disorder usually arising from mutations to the SERPINA1 gene that codes for AAT. The most common AATD alleles are S and Z which produce ~ 40% and ~ 90% reductions in serum AAT, respectively. Rare genetic variants (> 500 identified) can also be associated with mild to severe AATD.
RESULTS: This report describes a novel mutation of SERPINA1 producing AATD, which we have designated, Q0RİZE. This mutation was identified in a 44-year-old woman admitted with massive hemoptysis and treated with bronchial artery embolization. Computed tomography revealed centriacinar and panacinar emphysema with prominent air entrapment, atelectasis, and localized bronchiectasis. Serum AAT was < 0.27 g/L (below detection limit). Genetic analysis showed homozygous deletion of exons I to III.
CONCLUSIONS: Although many SERPINA1 variants have been identified, variants with large deletions and identified in a homozygous individual, as seen in this case with Q0RIZE, are uncommon. AATD is an underdiagnosed and undertreated disease. Wider screening of COPD patients could result in earlier diagnosis and treatment that could preserve lung function.
COVID-19 vaccination has been associated with myocarditis in adolescents and young adults, and concerns have been raised about possible vaccine-related cardiac fatalities in this age group. In April 2021, cases of myocarditis after COVID-19 vaccination, particularly among young male vaccine recipients, were reported to the Vaccine Adverse Event Reporting System. To assess this possibility, investigators searched death certificates for Oregon residents aged 16-30 years who died during June 2021-December 2022 for cardiac or undetermined causes of death. For identified decedents, records in Oregon's immunization information system were reviewed for documentation of mRNA COVID-19 vaccination received ≤100 days before death. Among 1,292 identified deaths, COVID-19 was cited as the cause for 30. For 101 others, a cardiac cause of death could not be excluded; among these decedents, immunization information system records were available for 88, three of whom had received an mRNA COVID-19 vaccination within 100 days of death. Of 40 deaths that occurred among persons who had received an mRNA COVID-19 vaccine dose, three occurred ≤100 days after vaccination. Two of these deaths were attributed to chronic underlying conditions; the cause was undetermined for one. No death certificate attributed death to vaccination. These data do not support an association between receipt of mRNA COVID-19 vaccine and sudden cardiac death among previously healthy young persons. COVID-19 vaccination is recommended for all persons aged ≥6 months to prevent COVID-19 and complications, including death.
The participants of this study were 33 subjects of both genders (M = 68 years old; SD = 4.2 years old) and were divided in two groups: a control group (N = 15; M = 67, 6 years old; SD = 4.1 years old) and an experimental group (N = 18; M = 67, 4 years old; SD = 4.4 years old). The participants performed a Soda Pop test before the aerobic training session (Baseline). The training session lasted 45 minutes and was composed of running exercises. After the training session, the motor memory consolidation was held in three different stages: Training; 1 hour after training; 24 hours after training.
PURPOSE:The titled substance obtained by treating microbial cells of Streptococcus faecium with hot water, and salting out the resultant extract. CONSTITUTION:An antitumor active substance obtained by cultivating a strain, e.g. Streptococcus faecium R 672 strain; FERM-P No.8167) belonging to Streptococcus faecium, and collecting the microbial cells from the culture by the centifugation, washing the micobial cells with physiological saline solution, etc., adding an adequate amount of purified water thereto, heating the resultant mixture, and extracting the substance with hot water. The amount of the purified water to be used for extraction with the hot water is 5-50 times, preferably 8-15 times based on the wet weight of the microbial cells. The extraction temperature is 4-100 deg.C. A salt, e.g. ammonium sulfate, is used to salt out the extract, and deposited precipitate is separated by filtration or centrifugation, etc., and the resultant residual salt is removed by dialysis, gel filtration, etc. The resultant precipitate is then freeze-dried to give the aimed antitumor active substance. The preferred dosage form is injection and transfusion solution, and the dose thereof is 1-2,000mg/day.
Disclosed are compositions, kits, and methods which are useful for the treatment of gastrointestinal conditions in mammals. In one embodiment, the disclosure is directed to a method of treating a gastrointestinal condition in a mammal in need of such treatment, wherein the method comprises administering to the mammal a composition comprising a non-glyceryl ester of a long chain fatty acid. In another embodiment, the invention is directed to a method of treating a gastrointestinal condition in a mammal in need of such treatment, wherein the method comprises administering to the mammal a bismuth component and a long chain fatty acid component. In yet another embodiment, the disclosure is directed to a kit comprising a composition comprising a non-glyceryl ester of a long chain fatty acid; and information that the composition is useful for the treatment of a gastrointestinal condition in mammals. In still another embodiment, the invention is directed to a kit comprising a long chain fatty acid component, a bismuth component, and information that the composition is useful for the treatment of a gastrointestinal condition in mammals. In yet another embodiment, the disclosure is directed to a composition comprising a long chain fatty acid component selected from the group consisting of long chain fatty acids, non-glyceryl esters of long chain fatty acids, and mixtures thereof, and a bismuth component.
All participants allocated to the interventional arm will receive the RT technique, dose and fractionation according to institutional standards. Once per week, participants will use a mobile phone 'app' to enter mPROs, and indicate a need for review for any other reason. The treatment Radiation Therapists will triage the participant to either attend or skip that week's on-treatment review based on this information and established criteria. After RT completion, Advanced Practice Radiation Therapists (apRTs) will triage the participant to receive a virtual follow-up visit when necessary. Participants will be seen once by a Radiation Oncologist 4 to 12 weeks after last radiation treatment. The participants will also complete the following questionnaires: 1) Baseline (patient factors); 2) 'During treatment' (review quality); 3) 'Post acute phase' (satisfaction with care). Circle-of-care HCP will comment on the impact of the PROMOTE process on the quality of care for that participant.
PURPOSE: Voice change is one of the major symptoms in patients with vocal fold polyp. As a result, phonomicrosurgery is commonly required in these patients. Since voice outcomes after polyp treatment can be variable according to polyp characteristics, we aimed to investigate the predicting factors of postoperative voice improvements in terms of polyp characteristics in patients with vocal fold polyp who underwent cold knife surgery.
MATERIALS AND METHODS: A total of 77 patients who were diagnosed with vocal fold polyp and underwent phonomicrosurgery with cold knife instruments. The polyp characteristics of color, size, shape, and location were evaluated at baseline. Acoustic and aerodynamic analyses, voice handicap index questionnaire and grade, roughness, breathiness, asthenia, strain scale were evaluated at baseline and 6 weeks after surgery.
RESULTS: All values of postoperative voice parameters improved after cold knife surgery. (P < 0.05) In patient with an organized vocal fold polyp, less improvement in postoperative values of maximum phonation time were observed. (P < 0.05) Likewise, less improvement of voice handicap index questionnaire score and grade, roughness, breathiness, asthenia, strain scale after surgery was shown in organized vocal fold polyp. (P < 0.05) CONCLUSIONS: Among the various polyp characteristics, the organized polyp was significantly related to relatively less improvement of objective and subjective voice parameters after surgery. These polyp characteristics would help to predict postoperative voice improvement and plan for personalized treatment in patients with vocal fold polyp.
PURPOSE: To obtain an inhibitor, containing hinokitiol as an active ingredient capable of manifesting excellent inhibiting activities against lipases, having high safety and useful for prevention from the deterioration of a food due to the lipases in the food containing oils and fats and prophylaxis, etc., of adult diseases. CONSTITUTION: This inhibitor contains hinokitiol as an active ingredient. The daily dose thereof for an adult is preferably 0.5-3000mg expressed in terms of the active ingredient. The amount of the blended active ingredient is respectively preferably 0.3-15wt.% in the case of peroral or mucosal absorption and 0.01-10wt.% in the case of parenteral administration. A formulation excellent in stability is obtained when the active ingredient is coated and prepared thereinto. When the inhibitor is blended in a food, it is preferably used in an amount of 0.001-10wt.%, expressed in terms of the active ingredient and based on the food.
In the self-selected exercise session, individuals will perform 30 min of exercise with self-selected intensity. This means that the duration of the series and the intensity (speed) of the treadmill are at the discretion of the patient. The important thing is that in the end it totals 30 minutes of exercise. This choice of intensity and duration of the series can be made regardless of the occurrence of pain.
Malignant pleural effusion cause significant morbidity so drainage effusion can provide great palliation and improve quality of life of these patients. There are several diagnostic tools for diagnosing malignant pleural effusion as pleural fluid cytology, closed pleural biopsy or thoracosopic pleural biopsy. Medical thoracoscopy has significant role in diagnosis and management of malignant pleural effusion. Also, pleurodesis may be performed through it by mechanical methods as pleural abrasion or chemical methods by talc poudrage, bleomycin or cisplatin instillation . and surgically through pleurectomy. Recently, using of ROSE (Rapis On-Site Examination) technique during medical thoracoscopy showed high accuracy for distinguishing between benign and malignant lesions, and this help in decision making. In our study, we will use mechanical pleurodesis by pleural abrasion using medical thoracoscpy and chemical pleurodesis by instillation of bleomycin via indwelling pleural catheter.
The participants in this group participate in multimodal exercise programs including aerobic exercise, balance, and strength training. The entire exercise program for the PE group will contain 10 minutes of warm-up, 70 minutes of physical exercise, and 10 minutes of cool-down. The 70 minutes of exercise session will be break up into 2 to 3 parts, and the participants can rest as needed during the exercise period.
A chatbot capable of empathic engagement with a user is disclosed. An identified trend in a user's mood or goals between a first time and a second time can be associated with open input (e.g., open text string input) from the user. As the user's mood or goals continue to be tracked, a subsequent trend can be identified that is the same as, similar to, different from, or opposite to the first identified trend. The user can then be automatically engaged based on the open input associated with the first identified trend. In an example, a user may input thoughts or reasons why they have been having a positively trending mood over a duration of time. The chatbot can then repeat or otherwise use those same thoughts or reasons to engage the user empathically when the chatbot detects that the user is experiencing a negatively trending mood.
Short-term protein-calorie dietary restriction (StDR) is a promising preoperative strategy for modulating postoperative inflammation. We have previously shown marked gut microbial activity during StDR, but relationships between StDR, the gut microbiome, and systemic immunity remain poorly understood. Mucosal-associated invariant T-cells (MAITs) are enriched on mucosal surfaces and in circulation, bridge innate and adaptive immunity, are sensitive to gut microbial changes, and may mediate systemic responses to StDR. Herein, we characterized the MAIT transcriptomic response to StDR using single-cell RNA sequencing of human PBMCs and evaluated gut microbial species-level changes through sequencing of stool samples. Healthy volunteers underwent 4 days of DR during which blood and stool samples were collected before, during, and after DR. MAITs composed 2.4% of PBMCs. More MAIT genes were differentially downregulated during DR, particularly genes associated with MAIT activation (CD69), regulation of pro-inflammatory signaling (IL1, IL6, IL10, TNFα), and T-cell co-stimulation (CD40/CD40L, CD28), whereas genes associated with anti-inflammatory IL10 signaling were upregulated. Stool analysis showed a decreased abundance of multiple MAIT-stimulating Bacteroides species during DR. The analyses suggest that StDR potentiates an anti-inflammatory MAIT immunophenotype through modulation of TCR-dependent signaling, potentially secondary to gut microbial species-level changes.